000			01914 a2200505 4500
005			20250512133826.0
264		0	_c19710628
008			197106s 0 0 eng d
022			_a0008-543X
024	7		_a10.1002/1097-0142(197104)27:4<835::aid-cncr2820270413>3.0.co;2-k _2doi
040			_aNLM _beng _cNLM
100	1		_aPanettiere, F
245	0	0	_aExperience with emetine hydrochloride (NSC 33669) as an antitumor agent. _h[electronic resource]
260			_bCancer _cApr 1971
300			_a835-41 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAdenocarcinoma _xdrug therapy
650	0	4	_aAntineoplastic Agents _xadverse effects
650	0	4	_aBreast Neoplasms _xdrug therapy
650	0	4	_aCarcinoma, Bronchogenic _xdrug therapy
650	0	4	_aCarcinoma, Squamous Cell _xdrug therapy
650	0	4	_aCarcinoma, Transitional Cell _xdrug therapy
650	0	4	_aColonic Neoplasms _xdrug therapy
650	0	4	_aDiarrhea _xchemically induced
650	0	4	_aElectrocardiography
650	0	4	_aEmetine _xadministration & dosage
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aInjections, Intravenous
650	0	4	_aLaryngeal Neoplasms _xdrug therapy
650	0	4	_aLeukemia, Lymphoid _xdrug therapy
650	0	4	_aLung Neoplasms _xdrug therapy
650	0	4	_aLymphoma, Large B-Cell, Diffuse _xdrug therapy
650	0	4	_aMale
650	0	4	_aMelanoma _xdrug therapy
650	0	4	_aMyositis _xchemically induced
650	0	4	_aNausea _xchemically induced
650	0	4	_aTachycardia _xchemically induced
650	0	4	_aThyroid Neoplasms _xdrug therapy
650	0	4	_aTracheal Neoplasms _xdrug therapy
650	0	4	_aUrinary Bladder Neoplasms _xdrug therapy
700	1		_aColtman, C A
773	0		_tCancer _gvol. 27 _gno. 4 _gp. 835-41
856	4	0	_uhttps://doi.org/10.1002/1097-0142(197104)27:4<835::aid-cncr2820270413>3.0.co;2-k _zAvailable from publisher's website
999			_c4932703 _d4932703